Document is current
Any future updates will be listed below
-
Authors
Deng, Mi
Gui, Xun
Kim, Jaehyup
Xie, Li
Chen, Weina
Li, Zunling
He, Licai
Chen, Yuanzhi
Chen, Heyu
Luo, Weiguang
Lu, Zhigang
Xie, Jingjing
Churchill, Hywyn
Xu, Yixiang
Zhou, Zhan
Wu, Guojin
Yu, Chenyi
John, Samuel
Hirayasu, Kouyuki
Nguyen, Nam
Liu, Xiaoye
Huang, Fangfang
Li, Leike
Deng, Hui
Tang, Haidong
Sadek, Ali H.
Zhang, Lingbo
Huang, Tao
Zou, Yizhou
Chen, Benjamin
Zhu, Hong
Arase, Hisashi
Xia, Ningshao
Jiang, Youxing
Collins, Robert
You, M. James
Homsi, Jade
Unni, Nisha
Lewis, Cheryl
Chen, Guo-Qiang
Fu, Yang-Xin
Liao, X. Charlene
An, Zhiqiang
Zheng, Junke
Zhang, Ningyan
Zhang, Cheng Cheng
- License Information
-
More Information
Article History
Received: 15 May 2016
Accepted: 15 August 2018
First Online: 17 October 2018
Competing interests
: The Board of Regents of the University of Texas System has filed patent applications with PCT Application Nos. PCT/US2016/020838, which covers anti-LILRB antibodies and their uses in detecting and treating cancer, and PCT/US2017/044171, which covers the methods for identifying LILRB-blocking antibodies. Authors C.C.Z., M.D., Z.A., N.Z., X.G. and J.Z. are listed as inventors of PCT/US2016/020838. Authors C.C.Z., Z.A., N.Z., M.D., J.K. and X.G. are listed as inventors of PCT/US2017/044171. Both patent applications have been exclusively licensed to Immune-Onc Therapeutics by the Board of Regents of the University of Texas System. Authors Z.A. and C.C.Z. are Scientific Advisory Board members with Immune-Onc Therapeutics, who also own equities and have a sponsored research agreement with Immune-Onc Therapeutics. Authors T.H. and X.C.L. are employees of and hold equities in Immune-Onc Therapeutics.
